Rachel Abbott

Company: Enara Bio

Job title: Senior Director, Head of TCR Pipeline and Dark Antigen Research

Seminars:

Overcoming Challenges of Classical TCR Targets with Novel, MR1 Cancer-Specific TCRs 9:30 am

Overview of the advances and potential patient benefit of TCR-based therapies Highlight challenges associated with traditional TCR targets, such as HLA restriction and antigen expression Introduce MR1 as an HLA-like target that appears to present cancerspecific ligands Present data and potential high-level development plans for TCRtargeting of MR1 in cancerRead more

day: Day One